Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Post-Surgical Crohn's Disease
NCT05784129Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Feb 2023; status: terminated.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05784129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784129.